SDI Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	**Ms_JPRI_53677**
Title of the Manuscript:	**Controlling post-operative pain intensity in patients undergoing tibia fracture surgery: Pregabalin vs. Clonidine**
Type of the Article	**Original Research Article**

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty'**, provided the manuscript is scientifically robust and technically sound.
To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline)

PART 1: Review Comments

	Reviewer's comment	**Author's comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Compulsory REVISION comments	1. There are many grammatical errors in this article. Correction is required 2. Abstract should be subdivided under following subtitles. Introduction, Methods, Results and conclusion. 3. **In abstract** : dose of 0,1 mg / kg. (Semicolon is used) Correction: dose of 0.1mg/kg 4. **In result**: showing no statically significant age differences. Correction: showing no statistically significant age differences.	The manuscript has been thoroughly modified
Minor REVISION comments	References are not arranged in any singular internationally recognized referencing style. References in the manuscript should be mentioned in superscript manner. E.g. [1]	
Optional/General comments	Keywords should be arranged in alphabetical order.	

PART 2:

	Reviewer's comment	**Author's comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Are there ethical issues in this manuscript?	*(If yes, Kindly please write down the ethical issues here in details)*	